Cantor Fitzgerald initiated coverage of Agios Pharmaceuticals with an Overweight rating and no price target. Cantor views Agios's Pyrukynd as an overlooked asset for two large, underserved hematology indications, thalassemia and sickle cell disorder, the analyst tells investors in a research note.